CytoMed Therapeutics (NASDAQ:GDTC) Shares Down 11% – What’s Next?

Shares of CytoMed Therapeutics Limited (NASDAQ:GDTC) dropped 11% during mid-day trading on Monday . The company traded as low as $0.8650 and last traded at $0.89. Approximately 33,556 shares were traded during mid-day trading, a decline of 5% from the average daily volume of 35,148 shares. The stock had previously closed at $1.00.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CytoMed Therapeutics in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

CytoMed Therapeutics Trading Down 11.0%

The stock’s 50 day simple moving average is $1.49 and its two-hundred day simple moving average is $1.83.

About CytoMed Therapeutics

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.